Latest and live tenders published in all country. Click on any tender to view further details.

emergency management, training and documentation services in the form of the following: advice in relation to compliance requirements, standards and practices; development and delivery of emergency management and response training; review and maintenance of current emergency management arrangements, plans and procedures; development and maintenance of emergency management arrangements, plans and procedures; provision of the emergency plan, including emergency response procedures, evacuation diagrams and training schedule for each nominated site; and provision of other services required as per any relevant statutory or legislative state or territory requirements.

approach to market atm is for the establishment of a deed of standing offer arrangement doso for the provision of a panel of experienced suppliers to provide end to end digitisation services for paper and printed materials, using procedures endorsed by the national archives of australia national archives. the national archives wishes to establish this panel for five years with options to extend at the sole discretion of the national archives.

provision of nsw and vic road worthy certificates for light, medium and heavy military vehicles

consultants and contractors to submit a tender for the development and delivery of a training program for itar and ear to be developed and delivered in melbourne, sydney, brisbane, adelaide, perth, and canberra to end june 2020. the training should provide defence smes with practical expertise and an understanding of current best practice for handling technologies controlled under itar or ear. the delivery and course material should be focused on an australian sme managing us export controlled items from a practical industry perspective, including examples of current best practice. at the completion of the training, sme participants should have developed a thorough understanding of the regulations and what is needed to ensure their companies handle controlled technologies appropriately. initiatives such as the us government’s ongoing export control reform and the australia – us defence trade controls treaty are to be addressed. additionally, there has been a shift in the jurisdiction of control from the itar to the ear following the us government’s export control reform agenda. given this, many australian defence smes need to revise and implement new processes to manage items under both jurisdictions. the training should address this issue. beyond the initial delivery of six workshops, there are three additional extension options, each comprising a minimum of 4 workshops and delivered in subsequent financial years.

falling number fn is a global industry standard used to quantify detrimental pre-harvest sprouting phs in wheat, as early release from seed dormancy leads to significant effects on end product quality. however, a low falling number can also be caused by the trait of late maturity alpha-amylase lma, with some wheats having a genetic predisposition to accumulate low levels of starch digesting enzymes during grain filling in the absence of sprouting. lma susceptibility is currently a classification criterion for milling wheat in australia. due to the cost involved in the current lma susceptibility screen, it is currently employed at a late phase in the breeding pathway of australian wheat breeding programs, which significantly restricts genetic gains for yield and other traits in australian wheat varieties. investment description this investment is one of three interrelated investments aimed at managing and eliminating the effect of late maturity alpha-amylase lma in wheat through improved phenotyping and modelling: proc-9176016 lma project a – improved phenotyping for late maturity alpha-amylase lma susceptibility in wheat; proc-9176017 lma project b – a novel high-throughput, low-cost test to determine cause of starch damage in wheat grain; and lma project c – an improved model of late maturity alpha-amylase lma field risk in australian wheat. this procurement focusses on the development of an innovative lma susceptibility screening methodology that has increased throughput, scalability, repeatability and significantly reduced costs in comparison to the current benchmark assay. it is expected that the successful applicant will propose a multi-disciplinary approach with potential inputs from fields such as phenomics, molecular biology, biometrics, plant physiology, plant breeding and genetics. innovative solutions may also borrow from other disciplines such as robotics, medical sciences, mathematics and engineering. the successful applicant will be expected to actively engage with industry stakeholders australian wheat breeding companies and wheat quality australia as well as the successful applicant of ‘lma project c – an improved model of late maturity alpha-amylase lma field risk in australian wheat’. expected outcome by 2030, late maturity alpha-amylase lma risk is managed within the australian wheat industry as to maximise genetic gains and minimise downgrades to improve enduring profitability for australian growers. intermediate outcome by 2023, australian industry will have access to accurate, high-throughput screening tools for lma expression that are employable early in breeding programs, research programs and applicable to a more cost effective, higher throughput lma classification screen; growers will have the ability to determine starch damage of grain on-farm; and the industry as a whole will have access to accurate field risk profiles of lma to inform decision making. this will be achieved through the three interrelated investments. expected output output 1 by 2023, an improved lma susceptibility screening methodology with increased throughput, scalability, repeatability and decrease cost in comparison to the current benchmark assay. contracting the investment will be contracted on a grdc standard research agreement two party.

falling number fn is a global industry standard used to quantify detrimental pre-harvest sprouting phs in wheat, as early release from seed dormancy leads to significant effects on end product quality. however, a low falling number can also be caused by the trait of late maturity alpha-amylase lma, with some wheats having a genetic predisposition to accumulate low levels of starch digesting enzymes during grain filling in the absence of sprouting. lma susceptibility is currently a classification criterion for milling wheat in australia. investment description this investment is one of three interrelated investments aimed at managing and eliminating the effect of late maturity alpha-amylase lma in wheat through improved phenotyping and modelling: proc- 9176016 lma project a – improved phenotyping for late maturity alpha-amylase lma susceptibility in wheat proc- 9176017 lma project b – a novel high-throughput, low-cost test to determine cause of starch damage in wheat grain; and lma project c – an improved model of late maturity alpha-amylase lma field risk in australian wheat. this tender is for the development of a rapid, mobile, low-cost test for starch degradation in wheat grains which can also determine the cause of damage as lma or phs. such a test will be valuable to breeders and pre-breeders seeking to determine the cause of starch damage in breeding material and research populations in the field, increasing the speed at which lma susceptibility can be controlled by genetics. the technology could also be used by growers to aid post-harvest decision making and by grain receivers to rapidly and reliably determine starch damage. it is expected that the successful applicant will propose an innovative approach that may include imaging science, biochemistry and/or molecular biology. the proposed approach may also borrow from other disciplines such as medical sciences, food sciences, physics and engineering. a proof of concept of the proposed approach will be highly regarded in assessment. the tender is open to private, public and private-public partnerships. expected outcome by 2030, late maturity alpha-amylase lma risk is managed within the australian wheat industry as to maximise genetic gains and minimise downgrades to improve enduring profitability for australian growers. intermediate outcome by 2023, australian industry will have access to accurate, high-throughput screening tools for lma expression that are employable early in breeding programs, research programs and applicable to a more cost effective, higher throughput lma classification screen; growers will have the ability to determine starch damage of grain on-farm; and the industry as a whole will have access to accurate field risk profiles of lma to inform decision making. this will be achieved through the three interrelated investments. expected output output 1 by 2023, test developed to quantify starch damage and determine the cause as lma and/or phs.

ansto’s vision is to be a global science, research and engineering partner with a reputation for tackling complex problems and delivering outcomes to create a more sustainable world. one of ansto’s core values is to be safe, secure and sustainable. we are seeking a contractor who can uphold these three key principles by providing a fully cross-skilled and integrated security and emergency response capability across all three ansto campuses, with a specific focus on counter surveillance technology for our lucas heights facility.

supply of special sized steel pallets for the purpose of stock management and storage. the pallets are to be used for the management of hazardous and dangerous goods material stored in drums of 200l nominal capacity. the drums will be arranged within the pallet for stacking, storage, stock management, and transport on site. a model of the steel pallet design required is shown in the specifications

supply of ansto is considering options for the optimisation and digitisation of its quality management system qms in particular in reference to its gmp health authority regulated organisations. the current quality management system is a mix of digital and paper based. ansto wants to focus on optimisation of each process and then digitisation and moving towards a best practice model.

brain cancer is the sixth leading cause of cancer burden and there are more than 100 types of brain cancer and other central nervous system cancers. these cancers carry high rates of morbidity and mortality. the five-year relative survival rate for brain cancer is low, at around 22 per cent. the young are disproportionately affected by brain cancer and brain cancer kills more children in australia than any other disease. despite improvements in patient care and support, survival rates for brain cancer have remained relatively unchanged for the past 30 years. the australian brain cancer mission the mission was announced on 29 october 2017 and aims to double survival rates and improve the quality of life for patients with brain cancer over ten years to 2027, with the longer term aim of defeating brain cancer. as at july 2019, $124.7m had been committed to the mission through co-investments from philanthropy, non-government organisations and governments, including $58.35m from the australian government through the medical research future fund mrff. cancer australia is responsible for administering the mission, supported by a strategic advisory group msag. a national brain cancer research roundtable was convened in 2017 bringing together people affected by brain cancer and their families, leading australian and international researchers, clinicians, advocacy and philanthropic groups. this roundtable provided the framework for delivery on the aim of the mission and developed a research roadmap that articulates the mission’s investment strategies. conducting an ‘analysis of australian brain cancer platforms and technologies’ is one of the early and immediate priorities for implementation outlined in the research roadmap. the purpose of the analysis is to inform future national infrastructure requirements and their use; identify networking strategies to enhance utilisation for platform and technology systems, and reduce duplication in effort; facilitate better coordinated use of platforms and technologies which will play a significant role in supporting brain cancer research, clinical trials, early detection, diagnosis, treatment and clinical care for children, adolescents and young adults aya, and adults with brain cancer for the next 3 – 5 years, and to 2027. scope: the scope of the analysis will cover platforms and technologies applicable to children, aya and adults with brain cancer across the brain cancer continuum of care, which for the analysis, will include brain cancer research, clinical trials, early detection, diagnosis, treatment, and clinical care. outcomes and reporting requirements: the analysis will inform future national infrastructure requirements, including how resources can be coordinated to play a significant role in supporting the brain cancer continuum of care for children, aya, and adults. the analysis will also identify existing platforms and technologies, as well as potential new platforms and technologies. in undertaking this work, the contractor will be required to provide cancer australia with monthly updates by teleconference, two progress reports, a draft final report and a final report. the two progress reports, the draft final report and the final report will also be considered by msag. the final report will include: 1.a review outlining brain cancer platforms and technologies that are currently available nationally and internationally, and how they are being used in australia; 2.a review of platforms and technologies currently used in cancer research and clinical trials, and where relevant, how these platforms and technologies can be incorporated across the brain cancer continuum of care to inform potential future investments under the mission over the next 3 - 5 years; and to 2027; 3.a review and the analysis of consultations with relevant experts identifying current platforms and technologies, and potential new platforms and technologies, that could inform the next investments under the mission to support the brain cancer continuum of care in australia, specifically: a. what is needed over the next 3 - 5 years; and b. what is on the horizon to 2027; and 4.an analysis of consultations with relevant experts identifying the workforce requirements, capacity, capability and training needs for the next 3 - 5 years and up to 2027, to support future investments in brain cancer platforms and technologies. 5.a gap analysis to inform future requirements across the brain cancer continuum of care in the next 3 – 5 years, and to 2027. the gap analysis will include: a.approaches to enhance utilisation of platform and technology system networks; b.proposals for how current and potential new platforms and technologies utilising large data sets and bioinformatics, can aid in achieving the aim of the mission; c.potential strategies for reduction of any identified duplications in resources in relation to brain cancer platforms and technologies across the continuum of care; and d.potential strategies to facilitate more efficient coordinated use of brain cancer platforms and technologies. 6.a cost-benefit analysis for upscaling current platforms and technologies, and introducing potential new platforms and technologies, to fill identified validated gaps from the above gap analysis. the cost-benefit analysis will include the costs and benefits to patients and the healthcare system in the next 3 – 5 years, and up to 2027, to inform potential future investments under the mission. 7.a plan for upscaling existing platforms and technologies, and the introduction of potential new platforms and technologies, including considerations for the identified critical parameters and elements, required for the upscaling and introduction of these platforms and technologies, to achieve expansion of the brain cancer continuum of care in the next 3 – 5 years and up to 2027. partnerships: cancer australia encourages the partnering of different organisations, departments, and groups to bring together the necessary skills and experiences to provide a tender to undertake the analysis. the organisational structure and management of staff involved in the partnership should be outlined in the tender. timeframe: the project is planned to commence in november 2019 and to be completed within six months of the start date. funding of up to $450, 000 gst inclusive has been provided from the department of health to cancer australia for the purpose of procuring a suitably qualified organisation to undertake this work.